2561 — Visen Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- HK$2.70bn
- HK$2.18bn
- CNY0.17m
Annual income statement for Visen Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 0.165 |
| Cost of Revenue | ||||
| Gross Profit | — | — | — | 0.019 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 288 | 249 | 182 | 252 |
| Operating Profit | -288 | -249 | -182 | -252 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -289 | -250 | -182 | -253 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -289 | -250 | -182 | -253 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -289 | -250 | -182 | -253 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -289 | -250 | -182 | -253 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -2.43 | -2.07 | -1.47 | -2.36 |